Scarica l'app Stockscreener
21.82
0.65%
0.14
Dopo l'orario di chiusura:
22.20
0.38
+1.74%
Precedente Chiudi:
$21.68
Aprire:
$21.62
Volume 24 ore:
617.29K
Relative Volume:
0.65
Capitalizzazione di mercato:
$1.40B
Reddito:
-
Utile/perdita netta:
$-221.04M
Rapporto P/E:
-5.8746
EPS:
-3.7143
Flusso di cassa netto:
$-178.65M
1 W Prestazione:
+5.97%
1M Prestazione:
+27.60%
6M Prestazione:
+52.91%
1 anno Prestazione:
+166.42%
Intervallo 1D:
$21.16
$22.37
Intervallo di 1 settimana:
$19.99
$22.54
Portata 52W:
$5.68
$22.54
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Nome
Cullinan Therapeutics Inc
Settore
Industria
Telefono
617-410-4650
Indirizzo
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
21.82 | 1.38B | 0 | -221.04M | -178.65M | -3.7143 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-17 | Iniziato | Citigroup | Buy |
| 2026-02-02 | Iniziato | Guggenheim | Buy |
| 2025-08-21 | Ripresa | H.C. Wainwright | Buy |
| 2025-06-11 | Ripresa | Stifel | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-05-01 | Iniziato | Stifel | Buy |
| 2024-04-15 | Iniziato | William Blair | Outperform |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-06-15 | Iniziato | TD Cowen | Outperform |
| 2022-11-21 | Iniziato | BTIG Research | Buy |
| 2021-04-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Iniziato | Evercore ISI | Outperform |
| 2021-02-02 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Iniziato | SVB Leerink | Outperform |
| 2021-02-01 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie
Blue Owl Capital Holdings LP Invests $28.04 Million in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Tokyo’s Taiho and Cullinan Announce Positive Phase 3 Lung Cancer Results - geneonline.com
Cullinan Therapeutics, Inc.Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
Is Cullinan Therapeutics (CGEM) Fully Valued After Its Phase 3 Trial Win? - simplywall.st
Taiho, Cullinan trial results selected for lung cancer conference By Investing.com - Investing.com Australia
Cullinan Therapeutics (CGEM) to Present Phase 3 REZILIENT3 Trial - GuruFocus
Taiho, Cullinan trial results selected for lung cancer conference - Investing.com
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer - marketscreener.com
Cullinan's lung cancer trial met its main goal; results are set for presentation in September - Stock Titan
Cullinan Oncology stock hits 52-week high at 21.55 USD By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Morgan Stanley Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 1-Year HighShould You Buy? - MarketBeat
UBS Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $27 - Moomoo
UBS raises Cullinan Oncology stock price target to $27 on trial data - Investing.com
HC Wainwright Reaffirms Buy Rating for Cullinan Therapeutics (NASDAQ:CGEM) - MarketBeat
CGEM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $30 - GuruFocus
Cullinan Therapeutics (CGEM) Advances in Phase 3 Trial, Shares Near 2-Year High Amid Mixed Signals - GuruFocus
Assenagon Asset Management S.A. Sells 77,023 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 30,000 Shares - MarketBeat
Cullinan Therapeutics (CGEM) investor group discloses 6,491,123-share position - Stock Titan
Cullinan Therapeutics (CGEM): T. Rowe Price reports 6.2% ownership stake - Stock Titan
CGEM (CGEM) insider to sell 30,000 shares after stock option exercise - Stock Titan
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Op - Benzinga
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up After Analyst Upgrade - MarketBeat
CGEM Maintains Outperform Rating -- Price Target Raised to $42.0 - GuruFocus
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $42.00 - MarketBeat
Cullinan Therapeutics (CGEM) Shares Rise 6% Premarket on Positiv - GuruFocus
New Taiho, Cullinan data heats up lung cancer drug battle - Yahoo Finance
Show Me The Money: Did You Miss CGEM's Rally? Here's What Comes Next - RTTNews
Cullinan rises on trial win for lung cancer drug (CGEM:NASDAQ) - Seeking Alpha
Cullinan: REZILIENT3 Phase 3 Interim Shows Improved PFS for Zipalertinib + Chemo - TradingView
Cullinan Therapeutics, Inc. $CGEM Shares Bought by The Manufacturers Life Insurance Company - MarketBeat
Cullinan Therapeutics Says Phase 3 Trial of Experimental Lung Cancer Drug Met Primary Endpoint - Yahoo Finance
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Report Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial in First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - marketscreener.com
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - BioSpace
Zipalertinib trial meets primary endpoint in lung cancer study - Investing.com Nigeria
Zipalertinib trial meets primary endpoint in lung cancer study By Investing.com - Investing.com Australia
HC Wainwright Issues Pessimistic Outlook for CGEM Earnings - MarketBeat
Biotech Stocks At 52-Week HighsALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH - RTTNews
Cullinan Oncology stock hits 52-week high at 19.43 USD By Investing.com - Investing.com UK
Cullinan says zipalertinib plus chemotherapy meets PFS endpoint in Phase 3 REZILIENT3 lung cancer trial - Bitget
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 52-Week HighStill a Buy? - MarketBeat
Possible Bearish Signals With Cullinan Therapeutics Insiders Disposing Stock - Moomoo
Cullinan Oncology stock hits 52-week high at 19.43 USD - Investing.com
Cullinan Therapeutics (CGEM) Wins FDA Backing For CLN 049, Is The Upside Already Priced In? - Sahm
Dimensional Fund Advisors LP Has $12.87 Million Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cullinan Therapeutics (NASDAQ:CGEM) Issues Quarterly Earnings Results - MarketBeat
Cullinan Therapeutics Inc Azioni (CGEM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):